Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Navenibart is in Phase 3 clinical development with top line data from the pivotal ALPHA-ORBIT trial expected in early 2027. The program is on track to support…
BioCryst will receive $70M upfront and will be eligible to receive up to $275M in future regulatory and sales milestone payments. BioCryst will also receive…
BioCryst (NASDAQ: BCRX) licenses navenibart in Europe for $70M upfront. The expansion leverages Neopharmed Gentili's existing European HAE infrastructure built…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BioCryst granted an Irish affiliate of Neopharmed Gentili exclusive rights to commercialize navenibart for hereditary angioedema in Europe. BioCryst receives $70M upfront, up to $275M in regulatory and sales milestones, and tiered royalties of 18% to 30% on net sales. Builds on the prior 2025 sale of BioCryst's European ORLADEYO business to Neopharmed Gentili.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Neopharmed Gentili S.p.A. (Irish affiliate) / BioCryst Pharmaceuticals, Inc. (this deal) | 2026 | $345M | — |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| AstraZeneca PLC / Amolyt Pharma | 2024 | $1.1B | 73 |
| Sanofi SA / Inhibrx Inc. | 2024 | $2.2B | 70 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2026 deals · Rare Disease deals